Article
Medicine, Research & Experimental
Cristina Valero, Mahdi Golkaram, Joris L. Vos, Bin Xu, Conall Fitzgerald, Mark Lee, Shannon Kaplan, Catherine Y. Han, Xin Pei, Reith Sarkar, Lillian A. Boe, Abhinav Pandey, Elizabeth S. Koh, Charlotte L. Zuur, David B. Solit, Traci Pawlowski, Li Liu, Alan L. Ho, Diego Chowell, Nadeem Riaz, Timothy A. Chan, Luc G. T. Morris
Summary: This study analyzed the clinical and genomic features of 133 ICB-treated patients with R/M HNSCC and identified 6 molecular subtypes that determine the response to ICB therapy. A predictive model based on clinical and genomic features outperformed the current biomarker of TMB alone. This validated predictive tool can help with clinical risk stratification in patients with R/M HNSCC considering ICB treatment.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Xin Zhou, Xiaoshen Wang
Summary: This review provides a detailed illustration of the biology, genomic features, and immune landscapes of HPV-associated HNSCC, supporting the synergistic effect of radioimmunotherapy. Current evidence and ongoing clinical trials suggest the potential of radioimmunotherapy in recurrent/metastatic or definitive settings. Future challenges include optimization of radiotherapy and the incorporation of novel therapeutic options.
Article
Oncology
Juliette Mainguene, Sophie Vacher, Maud Kamal, Abderaouf Hamza, Julien Masliah-Planchon, Sylvain Baulande, Sabrina Ibadioune, Edith Borcoman, Wulfran Cacheux, Valentin Calugaru, Laura Courtois, Carole Crozes, Marc Deloger, Elodie Girard, Jean-Pierre Delord, Antoine Dubray-Vautrin, Linda Larbi Cherif, Celia Dupain, Emmanuelle Jeannot, Jerzy Klijanienko, Sonia Lameiras, Charlotte Lecerf, Anouchka Modesto, Alain Nicolas, Roman Rouzier, Esma Saada-Bouzid, Pierre Saintigny, Anne Sudaka, Nicolas Servant, Christophe Le Tourneau, Ivan Bieche
Summary: The study found that HPV integration is associated with overexpression of certain cancer genes (such as PDL1 and MYC) in HNSCC patients. This may indicate a role of HPV integration in the carcinogenesis of HNSCC.
MOLECULAR ONCOLOGY
(2022)
Article
Cell Biology
Nupur Nigam, Benjamin Bernard, Samantha Sevilla, Sohyoung Kim, Mohd Saleem Dar, Daniel Tsai, Yvette Robbins, Kyunghee Burkitt, Cem Sievers, Clint T. Allen, Richard L. Bennett, Theophilus T. Tettey, Benjamin Carter, Lorenzo Rinaldi, Mark W. Lingen, Houssein Sater, Elijah F. Edmondson, Arfa Moshiri, Abbas Saeed, Hui Cheng, Xiaolin Luo, Kevin Brennan, Vishal Koparde, Chen Chen, Sudipto Das, Thorkell Andresson, Abdalla Abdelmaksoud, Madhavi Murali, Seiji Sakata, Kengo Takeuchi, Raj Chari, Yusuke Nakamura, Ravindra Uppaluri, John B. Sunwoo, Carter Van Waes, Jonathan D. Licht, Gordon L. Hager, Vassiliki Saloura
Summary: We identified SMYD3 as a mediator of immune escape in HPV-negative HNSCC. SMYD3 depletion upregulates type I IFN response and antigen presentation genes in HNSCC cells. Mechanistically, SMYD3 regulates the transcription of UHRF1, which binds to H3K9me3-enriched promoters of immune-related genes and silences their expression.
Article
Immunology
Xinwen Wang, Shouwu Wu, Feng Liu, Dianshan Ke, Xinwu Wang, Dinglong Pan, Weifeng Xu, Ling Zhou, Weidong He
Summary: By identifying ICD-associated subtypes, a new classification system based on ICD signatures can be established in HNSCC patients, which helps in assessing prognosis and effectiveness of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Vaishali Chandel, Saurabh Maru, Arun Kumar, Ashok Kumar, Ashok Sharma, Brijesh Rathi, Dhruv Kumar
Summary: Head and Neck tumors exhibit highly altered metabolism, with cancer cells utilizing different pathways for energy production. Monocarboxylate transporters play a crucial role in regulating lactate and maintaining pH balance, essential for cancer cell survival and growth control.
Article
Cell Biology
Zhang-Wei Hu, Yi-Hui Wen, Ren-Qiang Ma, Lin Chen, Xue-Lan Zeng, Wei-Ping Wen, Wei Sun
Summary: The study identified the ferroptosis driver SOCS1 and suppressor FTH1 as independent prognostic factors in head and neck squamous cell carcinoma, correlating with M1 and M2 macrophage infiltration. Targeting ferroptosis-immunomodulation may enhance immunotherapy efficacy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ming-Huei Chou, Hui-Ching Chuang, Yu-Tsai Lin, Ming-Hsien Tsai, Ying-Hsien Kao, I-Chun Lin, Tai-Lin Huang, Fu-Min Fang, Chih-Yen Chien
Summary: Advanced head and neck squamous cell carcinoma (HNSCC) patients have poor prognosis, but molecular targeted therapy, particularly targeting the mTOR pathway, shows promise as an effective treatment strategy. In this study, docetaxel was found to significantly inhibit HNSCC cell proliferation and migration via the PI3K/mTOR/CCL-20 signaling pathway. Additionally, mTOR inhibitors demonstrated dose-dependent inhibition of HNSCC cell growth and migration, showing synergistic effects when combined with docetaxel.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Adam J. Luginbuhl, Jennifer M. Johnson, Larry A. Harshyne, Alban J. Linnenbach, Sanket K. Shukla, Angela Alnemri, Gaurav Kumar, David M. Cognetti, Joseph M. Curry, Nikita Kotlov, Zoya Antysheva, Sandrine Degryse, Kyle Mannion, Michael K. Gibson, James Netterville, Brandee Brown, Rita Axelrod, Ralph Zinner, Madalina Tuluc, Stacey Gargano, Benjamin E. Leiby, Ayako Shimada, My G. Mahoney, Ubaldo Martinez-Outschoorn, Ulrich Rodeck, Young J. Kim, Andrew P. South, Athanassios Argiris
Summary: The addition of phosphodiesterase-5 inhibitor tadalafil to the PD-1 inhibitor nivolumab is safe and enhances immune-mediated antitumor responses in previously untreated squamous cell carcinoma of the head and neck. The combination therapy results in a pathologic treatment response of at least 20% in over 50% of the patients after 4 weeks of treatment. Pretreatment specimens show HPV status-dependent signatures that predict response to immunotherapy, while posttreatment specimens demonstrate an enhanced immune microenvironment with the addition of tadalafil.
CLINICAL CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Ching-Yun Hsieh, Ching-Chan Lin, Wei-Chao Chang
Summary: Taxanes, especially docetaxel, are widely used in combination therapy for head and neck squamous cell carcinoma (HNSCC) and have shown advantages in improving patient outcomes. Taxanes not only function as antimitotics, but also impair various oncogenic signaling pathways. However, the development of drug resistance remains a major obstacle to treatment response.
Article
Biochemistry & Molecular Biology
Torben Wilms, Linda Boldrup, Xiaolian Gu, Philip J. Coates, Nicola Sgaramella, Karin Nylander
Summary: This study revealed that high LDL levels are beneficial for survival outcome in patients with squamous cell carcinoma of the head and neck. Patients with high levels of total cholesterol or LDL had better overall survival. High LDL was identified as an independent prognostic factor for overall and disease-free survival.
Review
Biochemistry & Molecular Biology
Shengjian Jin, Yasusei Kudo, Taigo Horiguchi
Summary: Ubiquitination and deubiquitination are two common post-translational modifications of proteins, affecting their intracellular localization, stability, and function. Deubiquitination is involved in various cellular processes, including histone modification, cell cycle regulation, apoptosis, and cancer development. This review focuses on the understanding of the function of deubiquitinating enzymes in head and neck squamous cell carcinoma (HNSCC) and discusses potential therapeutic strategies for HNSCC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Kamila Romanowska, Agnieszka Sobecka, Agnieszka A. Rawluszko-Wieczorek, Wiktoria M. Suchorska, Wojciech Golusinski
Summary: Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, with molecular pathogenesis involving cell cycle disorders, intercellular signaling, proliferation, squamous cell differentiation, and apoptosis. In addition to genetic mutations, epigenetic alterations such as DNA methylation and histone modifications play a key role in promoting cancer formation and progression, making them potential biomarkers and therapeutic targets for HNSCC.
Review
Cell Biology
Chenhang Yu, Qiang Li, Yu Zhang, Zhi-Fa Wen, Heng Dong, Yongbin Mou
Summary: Head and neck squamous cell carcinoma (HNSCC) has a high incidence and mortality rate. Immunotherapy, with its potential for a broad and long-lasting antitumor response, has become an important therapeutic strategy for HNSCC. However, immune escape limits the effectiveness of immunotherapy. Various immunotherapy strategies, including immune checkpoint inhibitors, costimulatory agonists, antigenic vaccines, oncolytic virus therapy, adoptive T cell transfer, and targeted therapy, have been developed for HNSCC. Each strategy has its unique advantages, and their appropriate application has significant value for the treatment of HNSCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Editorial Material
Oncology
V. C. Sandulache, Y. L. Lei, L. E. Heasley, M. Chang, C. I. Amos, E. M. Sturgis, E. Graboyes, E. Y. Chiao, N. Rogus-Pulia, J. Lewis, A. Madabhushi, M. J. Frederick, A. Sabichi, M. Ittmann, W. G. Yarbrough, C. H. Chung, R. Ferrarotto, Weiyuan Mai, H. D. Skinner, U. Duvvuri, P. Gerngross, A. G. Sikora
Article
Immunology
Anthony R. Cillo, Cornelius H. L. Kuerten, Tracy Tabib, Zengbiao Qi, Sayali Onkar, Ting Wang, Angen Liu, Umamaheswar Duvvuri, Seungwon Kim, Ryan J. Soose, Steffi Oesterreich, Wei Chen, Robert Lafyatis, Tullia C. Bruno, Robert L. Ferris, Dario A. A. Vignali
Article
Oncology
Joel Thomas, Hong Wang, David A. Clump, Robert L. Ferris, Umamaheswar Duvvuri, James Ohr, Dwight E. Heron
FRONTIERS IN ONCOLOGY
(2020)
Article
Otorhinolaryngology
Viran Ranasinghe, Leila J. Mady, Seungwon Kim, Robert L. Ferris, Umamaheswar Duvvuri, Jonas T. Johnson, Mario G. Solari, Shaum Sridharan, Mark Kubik
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2020)
Article
Medicine, Research & Experimental
Hannah L. Schwarzbach, Leila J. Mady, Thomas M. Kaffenberger, Umamaheswar Duvvuri, Noel Jabbour
Summary: This study investigated the quality and readability of online information about HPV+ oropharyngeal cancer. The findings suggested that while the quality of information is high, the readability is poor, indicating the current online information may not be sufficient for public understanding. Improved patient education practices and resources are needed to address this issue.
Article
Medicine, Research & Experimental
Mark W. Kubik, Hani I. Channir, Niclas Rubek, Seungwon Kim, Robert L. Ferris, Christian von Buchwald, Umamaheswar Duvvuri
Summary: This retrospective study analyzed the role of transoral robotic base-of-tongue mucosectomy in patients with human papilloma virus negative unknown primary carcinoma. The results showed that only 3 out of 23 patients had a primary tumor identified in the base-of-tongue specimens.
Article
Oncology
Hui Li, Hoi-Lam Ngan, Yuchen Liu, Helen Hoi Yin Chan, Peony Hiu Yan Poon, Chun Kit Yeung, Yibing Peng, Wai Yip Lam, Benjamin Xiaoyi Li, Yukai He, Vivian Wai Yan Lui
Letter
Medical Laboratory Technology
William E. Gooding, Simion I. Chiosea
DIAGNOSTIC CYTOPATHOLOGY
(2021)
Article
Oncology
Zigui Chen, Po Yee Wong, Cherrie W. K. Ng, Linlin Lan, Sherwood Fung, Jing W. Li, Liuyang Cai, Pu Lei, Qianqian Mou, Sunny H. Wong, William K. K. Wu, Ryan J. Li, Katie Meehan, Vivian W. Y. Lui, Chit Chow, Kwok W. Lo, Amy B. W. Chan, Siaw Shi Boon, Eric H. L. Lau, Zenon Yeung, Kwan C. Allen Chan, Eddy W. Y. Wong, Alfred S. L. Cheng, Jun Yu, Paul K. S. Chan, Jason Y. K. Chan
Article
Oncology
Michael S. Landau, Yuri E. Nikiforov, N. Paul Ohori, Simion I. Chiosea
Summary: Some FNHCT nodules are AFTNs and oncocytic metaplasias, detectable based on characteristic mutations or lack of alterations on molecular testing. GH-CNAs characterize approximately half of histologically confirmed follicular oncocytic neoplasms among resected FNHCTs.
CANCER CYTOPATHOLOGY
(2021)
Article
Endocrinology & Metabolism
Simion Chiosea, Steven P. Hodak, Linwah Yip, Devaprabu Abraham, Chelsey Baldwin, Zubair Baloch, Seza A. Gulec, Zeina C. Hannoush, Bryan R. Haugen, Lija Joseph, Atil Y. Kargi, Elham Khanafshar, Masha J. Livhits, Bryan McIver, Kepal Patel, Snehal G. Patel, Gregory W. Randolph, Ashok R. Shaha, Jyotirmay Sharma, Nikolaos Stathatos, Annemieke van Zante, Sally E. Carty, Yuri E. Nikiforov, Marina N. Nikiforova
Summary: This study analyzed 50,734 thyroid nodule samples from 48,225 patients with Bethesda III-VI classification and found clinically relevant molecular alterations, including diagnostic, prognostic, and targetable genetic alterations. The study also demonstrated a 68% negative call rate in BCIII-IV nodules, indicating the potential for reducing unnecessary surgeries. Additionally, the study identified common genetic alterations in BCV-VI nodules, such as BRAF and TERT mutations, and targetable gene fusions.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Biochemical Research Methods
Ashley T. Fancher, Yun Hua, David A. Close, Wei Xu, Lee A. Mcdermott, Christopher J. Strock, Ulises Santiago, Carlos J. Camacho, Paul A. Johnston
Summary: This study prioritized three series of compounds that could block the interaction between androgen receptor (AR) and its coactivators, inhibit AR activity and inhibit the growth of prostate cancer cells. These compounds also reduced the expression and secretion of prostate specific antigen. Molecular docking analysis suggested that these compounds may bind to novel binding pockets on AR.
Article
Pathology
Jeremie Berdugo, Lisa M. Rooper, Simion I. Chiosea
Summary: RB1 loss is associated with a better disease free survival in p16-positive/HPV-negative oropharyngeal squamous cell carcinoma, while RB1 IHC does not provide additional prognostic information. RB1 inactivation rarely leads to false positive p16 IHC results. RB1 loss caused by the high-risk HPV E7 oncoprotein may coexist with RB1 deletion.
HEAD & NECK PATHOLOGY
(2021)
Article
Surgery
Meghan T. Turner, Mathew Geltzeiler, W. Greer Albergotti, Umamaheswar Duvvuri, Robert L. Ferris, Seungwon Kim, Eric W. Wang
JOURNAL OF ROBOTIC SURGERY
(2020)
Article
Pathology
Mark W. Kubik, Shaum Sridharan, Mark A. Varvares, Dan P. Zandberg, Heath D. Skinner, Raja R. Seethala, Simion Chiosea
HEAD & NECK PATHOLOGY
(2020)